8th May 2019 14:16
LONDON (Alliance News) - AstraZeneca PLC said Chief Financial Officer Marc Dunoyer purchased 8,500 shares in the pharmaceutical company on Tuesday at a price of GBP58.00 per share.
Dunoyer's holding following the GBP493,000 deal has not been disclosed.
On Tuesday, Astra announced results from its phase three trial of Calquence in chronic lymphocytic leukaemia. The trial demonstrated improvement to progression-free survival in patients taking Calquence.
Then, on Wednesday, Astra said its a phase two study of breast cancer drug trastuzumab deruxtecan had met its primary endpoint and confirmed the clinical activity seen in phase one.
Shares in AstraZeneca were up 1.2% at 5,833.00 pence on Wednesday afternoon in London.
Related Shares:
Astrazeneca